z-logo
open-access-imgOpen Access
Protection against LethalAspergillus fumigatusInfection in Mice by Allogeneic Myeloid Progenitors Is Not Major Histocompatibility Complex Restricted
Author(s) -
Caroline Arber,
Andrew BitMansour,
Sumana Shashidhar,
Sophia Y. Wang,
Benjamin Tseng,
J. Martin Brown
Publication year - 2005
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/491743
Subject(s) - aspergillus fumigatus , immunology , myeloid , biology , immunity , innate immune system , immune system , myeloid leukemia , progenitor cell , major histocompatibility complex , cancer research , stem cell , microbiology and biotechnology
Invasive fungal infections are a leading cause of morbidity and mortality after myelotoxic chemotherapy or radiation exposure. The resulting depletion of myeloid precursors under these conditions appears to be the factor that limits approaches to accelerate immune reconstitution. In a murine model of myeloablation after radiation exposure, we demonstrated that highly purified common myeloid and granulocyte-monocyte progenitors (CMPs/GMPs) accelerated myeloid recovery and, thus, enhanced innate immunity as measured by survival after a lethal challenge with Aspergillus fumigatus. Of greatest significance was the demonstration that the protection afforded by CMPs/GMPs was not major histocompatibility complex restricted. Furthermore, the effect of CMP/GMP cellular therapy was additive with that of liposomal amphotericin B treatment. These observations greatly expand the potential donor pool and, thus, the clinical utility of CMP/GMP cellular therapy in patients with myeloid depletion.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom